45th week of 2008 patent applcation highlights part 38 |
Patent application number | Title | Published |
20080274927 | Bicyclo(3.3.1)Nonanes and Bicyclo(3.3.1)Nonenes and Their Use as Flavor or Fragrance Ingredient - The present invention relates to substituted bicyclo[3.3.1]nonanes and bicyclo[3.3.1]nonenes of formula (I) | 2008-11-06 |
20080274928 | WATER SOLUBLE MAGNESIUM COMPOUNDS AS CLEANING AGENTS AND METHODS OF USING THEM - The present invention relates to compositions and methods employing a water soluble magnesium compound. In certain embodiments, the composition includes water and water soluble magnesium compound, but lacks other materials commonly used in cleaning compositions. The methods and compositions can provide magnesium ion at predefined ratios to calcium ion in water, such as magnesium ion in a molar amount equal to or in excess over a molar amount of calcium ion. A water soluble magnesium salt including an anion of a water soluble calcium salt is more effective than a magnesium salt with an anion of a water insoluble calcium salt. These compositions can be used for reducing lime scale or precipitate formation from hard water, removing soap scum, or the like. | 2008-11-06 |
20080274929 | METHOD FOR REMOVING MICROBES FROM SURFACES - A method has been found for the removal of microbial biofilm on surfaces in contact with systems, including but not limited to aqueous systems, which comprises adding to the aqueous system an effective amount of a polyethyleneimine surfactant to substantially remove microbial biofilm, from surfaces in aquatic systems, while presenting minimal danger to non-target aquatic organisms at discharge due to their very low discharge concentrations. | 2008-11-06 |
20080274930 | WAREWASHING COMPOSITION FOR USE IN AUTOMATIC DISHWASHING MACHINES, AND METHOD FOR USING - A warewashing composition includes a cleaning agent having a detersive amount of a surfactant, an alkaline source in an amount effective to provide a use composition having a pH of at least about 8 when the use composition is measured at a solids concentration of about 0.5 wt %, and a corrosion inhibitor in an amount sufficient for reducing corrosion of glass when the warewashing composition is combined with water of dilution at a dilution ratio of at least about 20:1 water of dilution to detergent composition o form a use composition. The corrosion inhibitor includes a salt of calcium, magnesium, or a mixture of calcium and magnesium. The salt has a water solubility of less than about 0.5 wt % in water at about 20° C. and atmospheric pressure so that the salt precipitates to form a protective layer on a substrate in contact with the use composition. | 2008-11-06 |
20080274931 | BIO-FRIENDLY AUTOMATIC DISH WASHING TABLETS PROCESSES AND ALL NATURAL PRODUCTS THEREBY - An improved process for manufacturing an all natural dish washing tablet having an inherent rinsing agent incorporated in the same and comprises, in combination, pre-blending sodium bicarbonate, combining the resultant blend with a plurality of granulated ingredients, adding an aliquot of liquid oil materials, including a warmed Glycerol Oleate component to create a master blend, and finishing the tablet. | 2008-11-06 |
20080274932 | COMPOSITION FOR IN SITU MANUFACTURE OF INSOLUBLE HYDROXIDE WHEN CLEANING HARD SURFACES AND FOR USE IN AUTOMATIC WAREWASHING MACHINES AND METHODS FOR MANUFACTURING AND USING - A composition useful in hard surface treatment and particularly useful in automatic warewashing is provided according to the invention. The composition may comprise a pretreatment composition, a detersive composition, a rinse agent composition or a combination thereof. The composition includes water-soluble cation and a source of alkalinity. The anionic alkaline source is selected from at least one of hydroxide anion or carbonate anion or a combination thereof. The cation is selected from magnesium, titanium, and aluminum, or combinations thereof. The source of alkalinity is provided in an amount effective to provide a use composition having a pH of greater than about 7. The cation is present in sufficient amount to form an in situ conversion agent. A conversion agent is a water-insoluble hydroxide precipitate that causes calcium in hard water to precipitate as aragonite thereby softening the water. The insoluble hydroxide reduces the contact angle of water on hard surfaces such as wares thus reducing water spotting. Methods for using and manufacturing such compositions are provided. | 2008-11-06 |
20080274933 | MG++ CHEMISTRY AND METHOD FOR FOULING INHIBITION IN HEAT PROCESSING OF LIQUID FOODS AND INDUSTRIAL PROCESSES - The present invention relates to methods for removing or preventing scale formation in a liquid food processing operation. Aqueous antiscalant solutions comprising soluble magnesium salts are used to prevent the precipitation of insoluble calcium salts and/or to increase the solubility of insoluble calcium salts. | 2008-11-06 |
20080274934 | INHIBITING THE CORROSIVE PROPERTIES OF LIQUID CLEANING AGENTS CONTAINING HYPOCHLORITE - A process for reducing the corrosive action of hypochlorite on metal surfaces in hypochlorite-containing aqueous liquid cleaning agents by the use of a combination of alkali hydroxide, alkali silicate, and alkyl(alkoxy) | 2008-11-06 |
20080274935 | Detergent Composition for Halogenated Dry Cleaning Solvents - A composition that optimizes the performance and maintenance of halogenated dry cleaning solvents is disclosed. One embodiment of a detergent composition for use with halogenated dry cleaning solvents includes water, a surfactant, a solubilizer, a coupling agent, an acid-accepting stabilizer, and a halogenated solvent. Optionally, the composition can include an oil-based fragrance and/or an optical brightener. When used in a dry cleaning process, the detergent composition replenishes the acid-accepting stabilizer depleted from the dry cleaning solvent and the halogenated solvent suppresses the flash point of the acid-accepting stabilizer. | 2008-11-06 |
20080274936 | HIGH ASH LIQUID LAUNDRY DETERGENTS - An aqueous based liquid laundry detergent comprises at least 15 wt. % of an alkali metal carbonate builder and a hygroscopic agent in sufficient amounts to maintain the stability of the detergent composition and reduce the formation of insoluble hydrates of the carbonate builder. | 2008-11-06 |
20080274937 | Coated Sodium Percarbonate Particles, Process For Their Production, Their Use And Detergent Compositions Containing Them - Coated sodium percarbonate particles, process for their preparation, their use and detergent compositions containing them Coated sodium percarbonate particles containing a sodium percarbonate core at least partially surrounded by at least one coating layer containing a hygroscopic compound, said hygroscopic compound being present in an amount such that the coated sodium percarbonate particles are capable of absorbing an amount of water (measured at an initial water content of less than 0.5% wt and after storage during 24 h at 32° C. and 50% RH) which is increased, compared to the uncoated sodium percarbonate core particles, with at least 0.1% of water per kg of coated sodium percarbonate particles. | 2008-11-06 |
20080274938 | Multiply-substituted protease variants with altered net charge for use in detergents - Novel protease variants derived from the DNA sequences of naturally-occurring or recombinant non-human proteases are disclosed. The variant proteases, in general, are obtained by in vitro modification of a precursor DNA sequence encoding the naturally-occurring or recombinant protease to generate the substitution of a plurality of amino acid residues in the amino acid sequence of a precursor protease. Protease variants are provided that contain substitutions of the amino acids at one or more residue positions so that the substitution alters the charge at that position to make the charge more negative or less positive compared to a precursor protease and thus the protease variant is more effective in a low detergent concentration system than a precursor protease. Also provided are protease variants containing substitutions of the amino acids at one or more residue positions so that the substitution alters the charge at that position to make the charge more positive or less negative compared to a precursor protease and thus the protease variant is more effective in a high detergent concentration system than a precursor protease. | 2008-11-06 |
20080274939 | WATER TREATMENT SYSTEM AND DOWNSTREAM CLEANING METHODS - The present invention provides methods for treating an aqueous system comprising contacting the aqueous system with a composition comprising a conversion agent. The methods of the present invention reduce the solubilized water hardness and/or reduce or inhibit scale formation in an aqueous system. Further, the methods of the present invention impact the chemistries needed in downstream cleaning processes employing water treated in accordance with the methods of the present invention. | 2008-11-06 |
20080274940 | Solidification matrix - A solid cleaning composition includes methacrylate, water, defoamer, carboxylate, sodium carbonate, metasilicate, and surfactant. The solid cleaning composition includes between about 1% and about 10% methacrylate by weight, less than about 5% water by weight, between about 1% and about 5% defoamer by weight, between about 10% and about 30% carboxylate by weight, between about 15% and about 80% sodium carbonate by weight, between about 1% and about 5% metasilicate by weight, and between about 1% and about 5% surfactant by weight. The solidification system may be used, for example, in a solid detergent composition. | 2008-11-06 |
20080274941 | DETERGENT OR CLEANSER DOSING UNIT - A process for manufacturing a detergent or cleaning agent dosing unit is comprised of the steps of: (a) providing a molded object of detergent or cleaning agent having at least one cavity having an orifice on the surface of the molded object wherein the cavity has a rim circumscribed about the edge of the orifice and wherein the rim has a width of at least 1 mm; (b) applying a first water-soluble film onto the rim; (c) filling the cavity; (d) applying a second water-soluble film over the filled cavity and sealing the cavity filled in step c). | 2008-11-06 |
20080274942 | SOLIDIFICATION MATRIX - A solidification matrix includes methacrylate, sodium carbonate, and water. The methacrylate, sodium carbonate, and water interact to form a hydrate solid having a growth exponent of less than about 3%. | 2008-11-06 |
20080274943 | Process for Producing Narrow Range Alkoxylates - According to the present invention there is provided a process for simultaneous or sequential separation of a mixture resulting from an alkoxylation reaction of a) at least one C4-C18 alcohol with b) at least one epoxide, comprising bringing said mixture into contact with pressurized CO2 having a concentration of at least 90% by weight, and collecting at least two fractions which differ in the average number of alkoxy units which are attached to said alcohol(s), at least a part of at least one but not all of said at least two fractions being recycled as raw material for the alkoxylation. | 2008-11-06 |
20080274944 | Sorbol Esters as Perfuming Ingredients - The present invention discloses perfuming ingredients, which are unsaturated esters of sorbol, as well as the use of such compounds in the perfumery industry and in compositions or articles containing such compounds. | 2008-11-06 |
20080274945 | Infant Nutrition With Protease Inhibitor - Provided is an infant nutrition comprising at least one protease inhibitor, a process for preparing such an infant nutrition and use of the infant nutrition for the treatment and/or prevention of childhood obesity and secondary disorders resulting from childhood obesity. | 2008-11-06 |
20080274946 | Method and composition for restoration of age related tissue loss in the face or selected areas of the body - A treatment method for restoring of age related tissue loss in the face or selected areas of the body is disclosed which includes injecting an injectable composition containing a growth factor and hyaluronic acid as a carrier into the dermis, the hypodermis, or both, in various areas of the face, or selected areas of the body of a person to stimulate collagen, elastin, or fat cell production, thereby restoring age related tissue loss in the face and selected areas of the body. Further disclosed is an injectable composition for restoring of age related tissue loss in the face and selected areas of the body, which contains a growth factor and hyaluronic acid as a carrier for providing time release of the growth factor into tissues. The growth factor can be insulin, insulin-like growth factor, thyroid hormone, fibroblast growth factor, estrogen, retinoic acid, or their combinations. | 2008-11-06 |
20080274947 | Hydroxy-Substituted Diphenylazetidinones for the Treatment of Hyperlipidemia - The present invention comprises compounds and compositions for the treatment of metabolic disorders and more particularly, those insulin-related metabolic disorders of the blood such as hyperlipidemia, diabetes, insulin-resistance and the like comprising diphenylazetidinones compounds which have an additional hydroxy function in the 2″ position and their salts. The invention therefore relates to compounds of formula I: | 2008-11-06 |
20080274948 | Conjugates of Hydroxyalkyl Starch and G-Csf - The present invention relates to conjugates of hydroxyalkyl starch and a granulocyte colony stimulating factor protein (G-CSF) wherein these conjugates are formed by a covalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. The present invention also relates to the methods of producing these conjugates and the use of these conjugates. | 2008-11-06 |
20080274949 | Formulation of Albumin-Free Erythropoietin - Disclosed is a stable pharmaceutical solution preparation of erythropoietin (EPO), which includes a stabilizing agent not containing a blood-derived protein, thereby maintaining EPO activity for a prolonged period of time without the risk of viral contamination. The stable solution preparation further includes a non-ionic surfactant and a tonicity agent, thereby preventing EPO loss during storage and facilitating administration to the body. | 2008-11-06 |
20080274950 | Cell Adhesion by Modified Cadherin Molecules - The potential role of so called ‘cell adhesion recognition motifs’ (CARs) in cadherin adhesion has been emphasized. Due to the importance of cadherin binding in biological process, there remains a need to develop effective ways of manipulating cadherin adhesion. According to the present invention, there is provided a pair of cadherin molecules modified to enhance intermolecular adhesion (i.e. adhesion or binding between the pair of cadherin molecules) compared with corresponding unmodified cadherin molecules. Intermolecular adhesion between the cadherin molecules may be enhanced by reducing or eliminating intramolecular binding within each cadherin molecule. For example, intramolecular binding may be reduced or eliminated by diminishing or preventing intramolecular binding of an N-terminal binding strand of each cadherin molecule with a binding strand acceptor pocket of each cadherin molecule. Additionally or alternatively, the intramolecular binding may be reduced or eliminated by diminishing or preventing the formation of an intramolecular ionic bond between the NH2 terminus of each cadherin molecule with a contact acidic amino acid residue of each cadherin molecule. | 2008-11-06 |
20080274951 | PHARMACEUTICAL COMPOSITIONS INCLUDING LOW DOSAGES OF DESMOPRESSIN - The present invention is directed to a pharmaceutical composition comprising 0.5 ng to 20 μg desmopressin and a pharmaceutically acceptable carrier. The present invention is also directed to a pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is effective to establish a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about 10.0 picogram desmopressin per mL plasma/serum. Articles of manufacture and methods of using the above invention are also disclosed. | 2008-11-06 |
20080274952 | Amylin Family Peptides And Methods For Making And Using Them - The present invention relates to obesity related polypeptides (ORPs), related nucleic acids, expression constructs, host cells, and processes production of the obesity related polypeptides. The ORPs of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk. | 2008-11-06 |
20080274953 | Method of Preparing a Protein Aggregate and a Pharmaceutical Preparation - The invention relates to a method of preparing a protein aggregate, wherein an aqueous protein solution is acidified with a pH that lies above the isoelectric point of the protein. In accordance with the invention, a first protein, which through acidification is able to form a protein aggregate, is acidified in the presence of a second protein in the aqueous solution in order to form a coaggregate comprising the first and second protein, wherein the second protein under identical temperature conditions and pH does not form a protein aggregate in the absence of the first protein. Acidification preferably occurs with the aid of CO | 2008-11-06 |
20080274954 | Gene Encoding a Guanine Nucleotide Exchange Factor and Its Gene Product - A gene encoding a novel protein having a guanine nucleotide exchange factor (GEF) activity for a Rho family protein being one group of small GTP binding proteins, namely, a polynucleotide shown by the nucleotide sequence set forth in SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO: 5, or the complementary strand, the equivalents of the polynucleotide, a protein encoded by the polynucleotide, a vector containing the polynucleotide, a transformant containing the vector, an antibody against the protein encoded by the polynucleotide, a method of identifying a compound that inhibits the function of the protein encoded by the polynucleotide and/or the expression of the polynucleotide, a method of determining a disease, a pharmaceutical composition, and a reagent kit are provided. | 2008-11-06 |
20080274955 | Novel Use of a Polypeptide Comprising Fas-1 Domain - The present invention relates to the novel use of a polypeptide comprising a fas-1 domain. More particularly, the invention relates to a method for the inhibition of the adhesion, migration and/or proliferation of endothelial cells, and/or for the inhibition of angiogenesis, using the polypeptide comprising the fas-1 domain, or functional equivalents thereof. Furthermore, the invention provides a method for treating or preventing angiogenesis-related diseases, using the polypeptide. | 2008-11-06 |
20080274956 | Fusion Protein Comprising a Bh3-Domain of a Bh3-Only Protein - This invention relates to a fusion protein comprising at least one first portion (I) comprising a trafficking sequence and at least one second portion (II) comprising a full-length or partial BH3-domain sequence of a BH3-only protein, said fusion protein comprising D-enantiomeric amino acids in retro-inverso order in its portion (I). Furthermore, the invention relates to pharmaceutical compositions containing said fusion protein as well as to the use of said fusion protein. | 2008-11-06 |
20080274957 | RGD-ENRICHED GELATINE-LIKE PROTEINS WITH ENHANCED CELL BINDING - The invention concerns a cell support comprising an RGD-enriched gelatine that has a more even distribution of RGD sequences than occurring in a natural gelatine and with a minimum level of RGD sequences. More precise the percentage of RGD sequences related to the total number of amino acids is at least 0.4 and if the RGD-enriched gelatine comprises 350 amino acids or more, each stretch of 350 amino acids contains at least one RGD motif. Preferably the RGD-enriched gelatines are prepared by recombinant technology, and have a sequence that is derived from a human gelatine or collagen amino acid sequence. The invention also relates to RGD-enriched gelatines that are used for attachment to integrins. In particular The RGD-enriched gelatines of the invention are suitable for coating a cell culture support for growing anchor-dependant cell types. Further, the RGD-enriched gelatines of the invention may find use in medical applications, in particular as a coating on implant or transplant material or as a component of drug delivery systems. | 2008-11-06 |
20080274958 | GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES - The present invention provides sequon polypeptides with an amino acid sequence including one or more exogenous O-linked glycosylation sequence of the invention. In addition, the present invention provides methods of making polypeptide conjugates as well as methods of using such conjugates and their pharmaceutical compositions. The invention further provides libraries of sequon polypeptides, wherein each member of such library includes at least one exogenous O-linked glycosylation sequence of the invention. Also provided are methods of making and using such libraries. | 2008-11-06 |
20080274959 | Actinomadura Chromoprotein, Apoprotein and Gene Cluster - The present invention provides a chromoprotein produced by | 2008-11-06 |
20080274960 | Fibrosis Inhibitor for Implanted Organ - A pharmaceutical preparation comprising a hepatocyte growth factor or a DNA molecule encoding the same and the like according to the present invention can suppress the fibrosis of a transplanted organ after organ transplantation. The present invention is useful in the fields of organ transplantation and regeneration therapy. | 2008-11-06 |
20080274961 | Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis - The present invention relates to peptides which are highly biologically and pharmacologically active as therapeutic drug for the treatment of diseases related to sarcoidosis. The peptides which can be used according to the invention for the treatment of said disease comprise at least one specific highly conservative amino acid residue sequence which seem to play an important role in connection with pulmonary and arteriolar hypertension events. It could be shown that the known naturally occurring peptides “vasoactive intestinal peptide (VIP)” and “pituitary adenylate cyclase-activating polypeptide (PACAP)”, having these specific sequences are potent drugs which can be successfully used for treatment of sarcoidosis. Furthermore, the present invention discloses a method for the treatment patients suffering from sarcoidosis. | 2008-11-06 |
20080274962 | Voltage Dependent Anion Channel (Vdac1) Compositions and Methods of Use Thereof for Regulating Apoptosis - The present invention relates generally to the mitochondrial protein, voltage-dependent anion channel (VDAC)5 polynucleotides encoding same and variants thereof, as well as peptide fragments, peptide derivatives and analogs. In particular, the present invention is directed to VDAC1 and specific amino acid and polynucleotide sequences thereof useful in inducing or regulating apoptosis and to pharmaceutical compositions comprising same useful in the treatment of diseases associated with aberrant apoptosis. | 2008-11-06 |
20080274963 | Modulation of Granulosa Cell Apoptosis - The present invention relates to a method of modulating apoptosis of a granulosa cell. The method includes one or more of the following steps: (i) modulating the concentration and/or activity of BMP-15 and/or BMP-6 that the granulosa cell is exposed to; (ii) modulating activity of a BMP-15 dependent signalling pathway in the granulosa cell; and (iii) modulating activity of a BMP-6 dependent signalling pathway in a granulosa cell. | 2008-11-06 |
20080274964 | Human Spasmolytic Polypeptide in Glycosylated Form - Human spasmolytic polypeptide (HSP) which has the amino acid sequence | 2008-11-06 |
20080274965 | ENCAPSULATED AMYLOID-BETA PEPTIDES - The present invention relates to the field of polymer chemistry and more particularly to encapsulated peptides and uses thereof. | 2008-11-06 |
20080274966 | Biglycan and related therapeutics and methods of use - The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders. | 2008-11-06 |
20080274967 | Variants of Pigment Epithelium Derived Factor and Uses Thereof - The present invention relates to anti-angiogenic variants of pigment epithelium derived factor (PEDF) comprising a plurality of altered phosphorylation sites, polynucleotides encoding same and uses thereof. In particular, the PEDF variants of the present invention provide superior anti-angiogenic activity and high neurotrophic activity and are useful in treating diseases associated with neovascularization and with neurodegenerative conditions. | 2008-11-06 |
20080274968 | IN VITRO METHODS FOR DETECTING RENAL CANCER - The present invention refers to an in vitro method for detecting the presence of renal cancer in an individual, for determining the stage, malignancy or severity of said carcinoma in the individual or for monitoring the effect of the therapy administered to an individual having said cancer; to the search, identification, development and assessment of the efficacy of compounds for therapy for said cancer in an attempt to develop new drugs; as well as to agents inducing Plexin-131 protein expression and/or activity, or to agents inhibiting the effects of Plexin-B1 protein expression and/or activity repression. | 2008-11-06 |
20080274969 | Albumin-Fused Kunitz Domain Peptides - The invention relates to proteins comprising serine protease inhibiting peptides, such as Kunitz domain peptides (including, but not limited to, fragments and variants thereof) fused to albumin, or fragments or variants thereof. These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules and vectors encoding the albumin fusion proteins of the invention, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting neutrophil elastase, kallikrein, and plasmin. The invention further relates to compositions and methods for treating cystic fibrosis and cancer. | 2008-11-06 |
20080274970 | VASCULAR ADHESION MOLECULES AND MODULATION OF THEIR FUNCTION - The invention relates to new polypeptides in isolated form belonging to a subfamily of the human immunoglobulin superfamily, which polypeptide shows at least 70% sequence homology with the amino acid sequence of the murine Confluency Regulated Adhesion Molecules 1 or 2 (CRAM-1 or CRAM-2) as depicted in FIG. | 2008-11-06 |
20080274971 | Use of ACRP30 Globular Head to Promote Increases in Muscle Mass and Muscle Differentiation - The present invention relates to the field of muscle research, in particular to the discovery of a compound effective for increasing muscle mass, muscle cell differentiation, and oxidation of free fatty acids in muscle, useful in methods of treating muscle-related diseases and disorders as well as for augmenting muscle mass in general. The muscle-related diseases or disorders envisaged to be treated by the methods of the invention include, but are not limited to, muscular dystrophy, and other conditions resulting in muscle atrophy or muscle wasting. | 2008-11-06 |
20080274972 | T-CELL EPITOPE PEPTIDES - The T-cell epitope site on a Japanese cypress (hinoki) pollen allergen molecule has been identified by stimulating a T-cell line established from a patient suffering from Japanese cypress pollen allergy with an overlap peptide covering the primary structure of the Japanese cypress pollen allergen. The peptide is useful in peptide-based immunotherapy for patients with spring tree pollinosis including patients with Japanese cypress pollinosis having cross reactivity with Japanese cypress pollen. The peptide is also useful for diagnosing spring tree pollinosis. | 2008-11-06 |
20080274973 | NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME - The present invention relates generally to a novel haemopoietin receptor or components or parts thereof and to genetic sequences encoding same. The receptor molecules and their components and/or parts and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor. | 2008-11-06 |
20080274974 | PROCESS FOR REMOVING VIRUSES IN FIBRINOGEN SOLUTIONS AND FIBRINOGEN OBTAINED BY SAID PROCESS - A process for removing viruses in fibrinogen solutions and fibrinogen obtained thereof wherein the process starts with an adjusted purified fibrinogen solution, the adjusted purified solution is frozen and then thawed at a temperature between 5 and 20° C., the undissolved materials associated with the fibrinogen are subsequently separated, the temperature is adjusted and the resultant solution is finally subjected to nanofiltration using filters having a pore size smaller than 35 nm. | 2008-11-06 |
20080274975 | Methods and Compositions for Inhibiting Abad/Abeta Protein Interaction - This invention provides methods, compositions and articles of manufacture for inhibiting binding between Aβ protein and ABAD in cells. Uses of this invention include, for example, treating Alzheimer's disease; reducing free radical generation, DNA fragmentation, and cytochrome C release in cells; and preserving cell viability by preventing LDH release from a cell. | 2008-11-06 |
20080274976 | USES OF NOVEL POTASSIUM CHANNEL BLOCKERS - The present invention is directed to kappaM (κM) conopeptide RIIIK and its use for blocking the flow of potassium ions through voltage-gated potassium channels. The κM conopeptides include unglycosylated and O-glycosylated peptides. | 2008-11-06 |
20080274977 | Treating stroke and other diseases without inhibiting N-type calcium channels - The invention provides methods for treating stroke and compositions for use in the same. The methods employ a chimeric peptide of an active peptide and an internalization peptide. The internalization peptide is a tat variant that promotes uptake of itself and a linked active peptide into a cell without substantial binding to N-type calcium channels. Use of the tat variant allows treating of stroke free of certain side effects associated with binding to N-type calcium channels. Tat variant peptides can also be linked to other active agent for use in treating other diseases. | 2008-11-06 |
20080274978 | Peptides That Antagonize Fpr Class Receptor Mediated Signaling - The present application discloses W-rich peptide that is useful for inhibiting FPR class receptor activity. | 2008-11-06 |
20080274979 | TREATMENT OF LEAKY OR DAMAGED TIGHT JUNCTIONS AND ENHANCING EXTRACELLULAR MATRIX - Self assembling peptides and peptidomimetics can be utilized for the treatment and support of disorders associated with leaky or damaged tight junction and weak, diseased, or injured extracellular matrix. The self-assembling materials generally have alternating hydrophilic or hydrophobic residues or hydrophobic and/or hydrophilic sections which allow the material to react or interact with the glycoproteins found in the ECM. Diseases in which treatment with these materials applied to or near the site in need of treatment include diabetic retinopathy, sepsis, burns, and certain neurodegenerative diseases such as Parkinson's and Alzheimer's. The formulations can be administered by injection, spraying, topically or by catheter or via a wound dressing or other material to which it is applied and then applied to the site in need of treatment. | 2008-11-06 |
20080274980 | MACROMONOMERS AND HYDROGEL SYSTEMS USING NATIVE CHEMICAL LIGATION, AND THEIR METHODS OF PREPARATION - The present invention provides novel biocompatible macromonomers, hydrogels, methods of synthesis and methods of use thereof. The biocompatible hydrogels of the present invention are prepared using native chemical ligation (NCL), in which a thioester readily reacts with a N-terminal thiol (cysteine) through transesterification and rearrangement to form an amide bond through a five-member ring intermediate. | 2008-11-06 |
20080274981 | Compositions and methods for regulating apoptosis - Peptides and peptidomimetics capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins) are disclosed. The peptides and mimetics are based on the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptides and peptidomimetics for therapeutic purposes and for rational drug design. | 2008-11-06 |
20080274982 | Peptide Substance Restoring Respiratory Organs Function - The invention refers to the medicinal remedies for respiratory system diseases treatment and may be applied as a substance, capable of restoring respiratory organs functions and used for treatment of different forms of lung pathology. There is proposed a biologically active new tetrapeptide alanyl-glutamyl-aspartyl-leucine of the general formula Ala-Glu-Asp-Leu, capable of restoring respiratory organs function. There is proposed a pharmaceutical substance, containing as an active peptide agent an effective amount of tetrapeptide alanyl-glutamyl-aspartyl-leucine of the general formula Ala-Glu-Asp-Leu, which if used in the medical preparation contributes to the restoration of the respiratory organs function. | 2008-11-06 |
20080274983 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases - Ophthalmically acceptable compositions used in arresting the development of cataracts or macular degeneration comprising a pharmaceutically acceptable carrier or diluent and a compound having the formula: | 2008-11-06 |
20080274984 | METHOD, COMPOSITION AND KIT FOR ANTIGENIC BINDING OF NORWALK-LIKE VIRUSES - A method for detecting a Norwalk-Like Virus (NLV) in a biological sample, comprising the steps of: obtaining a biological sample suspected of containing a NLV; contacting the biological sample with at least one human histo-blood group antigen to allow formation of a complex of the NLV with the antigen; and detecting the antigen-NLV complex. The antigen-NLV complex can be detected by contacting the NLV-antigen complex with a NLV antibody that binds at an epitope of the NLV, and detecting the NLV antibody. The invention also includes a method for identifying compounds, and the compounds, that can inhibit the binding between a Norwalk-Like Virus (NLV) and a histo-blood group antigen. The method includes the steps of contacting the NLV target with a compound; subsequently contacting the NLV with a standard compound that is known to be bound at a determinant binding site of the NLV; and determining whether the binding of the standard compound is decreased in the presence of the test compound, the decrease in binding being an indication that the test compound inhibits the binding activity of the NLV with the standard compound. In preferred embodiments, the standard compound is a histo-blood group antigen. | 2008-11-06 |
20080274985 | Pharmaceutical composition useful for the treatment of peptic ulcer diseases - The present invention deals with the pharmaceutical composition comprising the therapeutically effective amount of a compound oenothein C obtained from the bioactive fraction of plant | 2008-11-06 |
20080274986 | PHARMACEUTICAL VEHICLE - A pharmaceutical solution is capable of being ejected from a thermal fluid ejection device onto a substrate. The solution includes a vehicle with predetermined properties, and an active pharmaceutical ingredient with a solubility of at least about 30 mg/ml in the vehicle. The vehicle substantially evaporates from the substrate. | 2008-11-06 |
20080274987 | Novel alpha glucosidase activator, pulicarside 1 - A new ent-kaurane type diterpene glucoside, pulicarside (1) was isolated from | 2008-11-06 |
20080274988 | Microarray-Mediated Diagnosis of Herpes Virus Infection by Monitoring Host's Differential Gene Expression Upon Infection - The present invention discloses disease-associated molecules and assays, which are useful for diagnosing and assessing those animals with herpes virus infection, and determining those animals at risk of developing an herpes virus infection or its sequelae. The invention has practical use in the early diagnosis of disease, in monitoring an animal's immune response to the disease, and in enabling better treatment and management decisions to be made in clinically and sub-clinically affected animals. | 2008-11-06 |
20080274989 | Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof - The present invention is directed to small interfering RNA molecules (siRNA) targeted against nucleic acid sequence that encodes huntingtin or ataxin-1, and methods of using these siRNA molecules. | 2008-11-06 |
20080274990 | Cog47 Protein and S100beta Gene Polymorphism - The invention concerns a Cog | 2008-11-06 |
20080274991 | Nucleic Acids Against Viruses, in Particular Hiv - The invention provides a nucleic acid molecule comprising a sequence that is complementary to a mutant of a genomic nucleic acid sequence of an organism capable of mutating its genome. The genomic nucleic acid sequence preferably comprises a conserved, essential region. Furthermore, the genomic nucleic acid sequence preferably comprises a coding sequence and a DNA/RNA regulatory sequence. A pharmaceutical composition and a gene delivery vehicle comprising a nucleic acid molecule of the invention is also provided, as well as a method for counteracting an organism comprising providing the organism with the nucleic acid molecule. The organism is preferably additionally provided with a nucleic acid sequence complementary to a genomic nucleic acid sequence of the organism. | 2008-11-06 |
20080274992 | RECOMBINANT MODIFIED ANKARA VIRAL HIV-1 VACCINES - The field of the present invention relates to novel recombinant MVA vectors encoding one or more HIV-1 immunogens as an HIV-1 vaccine candidate and methods of using same. | 2008-11-06 |
20080274993 | Methods and compositions for modulating vascular integrity - The invention provides methods and compositions useful for modulating vascular integrity. | 2008-11-06 |
20080274994 | CARDIAC MYOSIN LIGHT CHAIN KINASE AND METHODS OF USE - The present disclosure provides a cDNA, protein sequence, and genomic structure of the human cardiac isoform of myosin light chain kinase (cMLCK), and describes mutations in the cMLCK gene that are associated with cardiac dysfunction. Methods are provided for identifying individuals who can harbor mutations in the cMLCK gene, or carry alleles that can predisposed them to cardiac dysfunction. Disclosed also is a significant role for cMLCK in modulating cardiac contractility. The cMLCK protein is shown herein to reduce the amplitude of stretch activation and increase the tension production, a property of muscle which has heretofore had an unknown role in cardiac contraction. Moreover, the cMLCK protein is shown to be regionally distributed in the heart, thereby having differential effects on contractility and stretch activation. Methods herein are provided to exploit this effect of cMLCK, to treat individuals who have or are prone to cardiac dysfunction. In addition, methods are provided to identify agents that modulate cMLCK activity, thereby having potential therapeutic importance in the treatment of cardiac dysfunction. | 2008-11-06 |
20080274995 | Suppression of Nuclear Factor-KappaB Dependent Processes Using Oligonucleotides - Antisense oligonucleotides which hybridize with nuclear factor-κB (NF-κB) mRNA and methods of using these oligonucleotides. | 2008-11-06 |
20080274996 | RNAi Probes Targeting Cancer-Related Proteins - RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment. | 2008-11-06 |
20080274997 | Stable Granulates Containing S-adenosylmethionine and Process for Preparation Thereof - A fluid bed granulation process for manufacturing non-hygroscopic, stable granulates containing a water-soluble salt of S-adenosylmethionine is described. Said process comprises: | 2008-11-06 |
20080274998 | Disaccharide Molecules and Derivatives Thereof and Methods of Using Same - The present invention is of a method and compounds for mediating a biological activity mediated by moesin, and in particular, for such a method and compounds for mediating a biological activity that is capable of being mediated through binding of a disaccharide to moesin. | 2008-11-06 |
20080274999 | Hyaluronic Acid Fraction with Moisturizing and Anti-Wrinkle Properties - A moisturizing, cosmetic, or anti-wrinkle product comprising hyaluronic acid or a salt thereof, wherein the hyaluronic acid or salt thereof has an average molecular weight in the range of 0.7-0.9 MDa, compositions comprising said product, and uses of said product. | 2008-11-06 |
20080275000 | COMPOSITIONS FOR REDUCING, AMELIORATING, TREATING, OR PREVENTING CONDITION OF DRY EYE AND METHODS OF MAKING AND USING SAME - Compositions for relief, treatment, or prevention of a condition of dry eye comprise alginate, a polyol, and a combinations of at least two organic acids or salts thereof, wherein the compositions have pH in the range from about 5 to about 7.5, at least one of the organic acids or salts thereof has a pKa in the range from and 6 to about 10. In some embodiments, the second organic acid or a salt thereof has a pKa that is no more than 1.5 units less than the pH. | 2008-11-06 |
20080275001 | SOLID ORAL DOSAGE FORM CONTAINING AN ENHANCER - The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form. | 2008-11-06 |
20080275002 | Method for Treatment of Hepatic Cancer - A method for therapeutic treatment of hepatic cancer, which comprises the step of administering 10 to 30 mg per day of 4-[3,5-bis(trimethylsilyl)benzamido]-benzoic acid or a physiologically acceptable salt thereof to a patient with hepatic cancer. | 2008-11-06 |
20080275003 | Bis-Cationic Compounds and Use Thereof - The present invention relates to bis-cationic compounds comprising quaternary ammonium groups and/or quaternary phosphonium groups. The invention also relates to the use of bis-cationic compounds as Phospholipase B inhibitors and the use of bis cationic compounds for the treatment or prevention of microbial infection. | 2008-11-06 |
20080275004 | N-Substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase - N-substituted 5-hydroxypyrimidin-6-one-4-carboxamides of formula: | 2008-11-06 |
20080275005 | MITOCHONDRIALLY TARGETED ANTIOXIDANTS - The invention provides mitochondrially targeted antioxidant compounds. A compound of the invention comprises a lipophilic cation covalently coupled to an antioxidant moiety. In preferred embodiments, the lipophilic cation is the triphenyl phosphonium cation, and the compound is of the formula P(Ph | 2008-11-06 |
20080275006 | Process for the Preparation and Isolation of Phosphatides - Process for the preparation of phosphatidylserine of formula | 2008-11-06 |
20080275007 | CHARGED PHOSPHOLIPID COMPOSITIONS AND METHODS FOR THEIR USE - The invention provides a pharmaceutical composition comprising a synthetic or naturally occurring charged phospholipid, which is formulated into a dosage form for administration to a subject or which is administered as a food additive. Negatively charged phospholipid composition increase the net negative charge on intravascular lipoproteins, enhance the clearance of cholesterol and regulate the function of lipolytic enzymes, retard prothrombin formation and aid in the clearance of virus and bacterial particles. Negatively charged lipid compositions can therefore be administered to humans and animals for the treatment of hyperlipidemia and blood coagulation disorders and to reduce the levels of virus, bacteria, and endotoxins in the blood stream. Positively charged lipid compositions can be administered to delay lipoprotein clearance from the plasma compartment and give longer duration of activity for drugs which are associated with lipoproteins. | 2008-11-06 |
20080275008 | Aminophosphonic acid derivative, salt thereof, and modulator of sip receptor - Aminophosphonic acid derivatives (e.g., 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonate monoester) are represented by the following general formula (1): | 2008-11-06 |
20080275009 | ORAL ADMINISTRATION OF N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO]-1,3-THIAZOLE-5-CARBOXAMIDE AND SALTS THEREOF - Disclosed are a method of treating cancer and/or other proliferative diseases comprising orally administering N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide or a salt thereof, and pharmaceutical compositions comprising N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide or a salt thereof. Also disclosed are N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide salts, as well as crystalline forms thereof. | 2008-11-06 |
20080275010 | COMPOSITIONS AND METHODS TO PREVENT TOXICITY INDUCED BY NONSTEROIDAL ANTIINFLAMMATORY DRUGS - Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compositions comprising (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly donates, transfers or releases a nitrogen monoxide group (preferably as a charged species, particularly nitrosonium); and methods of treatment of inflammation, pain, gastrointestinal lesions and/or fever using the compositions are disclosed. The compounds and compositions protect against the gastrointestinal, renal and other toxicities that are otherwise induced by nonsteroidal antiinflammatory drugs. | 2008-11-06 |
20080275011 | USE OF DIPYRIDAMOLE, ACETYLSALICYLIC ACID AND AN ANGIOTENSIN II ANTAGONIST FOR TREATMENT AND PREVENTION OF VASCULAR EVENTS - This invention relates to a method of treating and preventing vascular events and circulatory disorders in a patient in need thereof, especially in a patient at risk for said indications, using dipyridamole in combination with acetylsalicylic acid (ASA) and an angiotensin II antagonist, corresponding pharmaceutical compositions, and the use of dipyridamole for the manufacture of a corresponding pharmaceutical composition comprising a combination of dipyridamole, acetyl salicylic acid and an angiotensin II antagonist. | 2008-11-06 |
20080275012 | Pharmaceutical Composition - A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition. | 2008-11-06 |
20080275013 | Pharmaceutical Composition - A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition. | 2008-11-06 |
20080275014 | Clobetasol Propionate Shampoos for the Treatment of Seborrheic Dermatitis of the Scalp - Seborrheic dermatitis is effectively/safely treated by topically applying a corticosteroid shampoo, notably a clobetasol propionate shampoo, onto the scalp of a human subject afflicted therewith. | 2008-11-06 |
20080275015 | Formulation and Method for Treating Interstitial Cystitis and Related Bladder Conditions - The invention of this application relates to a formulation and method of using the formulation for the treatment of interstitial cystitis and other similar conditions of the bladder. The formulation of this invention is a highly specialized, compounded pharmaceutical that contains a combination of numerous therapeutically different medications in a unique delivery vehicle and system. The individual components of the formulation work synergistically to restore and repair each of the different issues associated with interstitial cystitis. The individual components of the formulation exist in an aqueous vehicle to facilitate drug contact with the bladder wall. The formulation is instilled directly into the bladder, commonly in a physician's office. | 2008-11-06 |
20080275016 | FULVENE AND FULVALENE ANALOGS AND THEIR USE IN TREATING CANCERS - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are fulvene and/or fulvalene analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, as well as numerous inflammatory, degenerative and vascular diseases, including various ocular diseases. Representative fulvene and/or fulvalene analogs include fulvene and fulvalene analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function, at least, by inhibiting Nox or ROS. In some embodiments, the Nox is one that is selectively expressed in cancer cells over normal cells, or one that is expressed in higher amounts in cancer cells over normal cells. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases. | 2008-11-06 |
20080275017 | AROMATIC SULFENATES FOR TYPE I PHOTOTHERAPY - Novel sulfenate derivatives and their bioconjugates for phototherapy of tumors and other lesions. The sulfenates of the present invention are designed to absorb low-energy ultraviolet, visible, or near-infrared (NIR) region of the electromagnetic spectrum. The phototherapeutic effect is caused by direct interaction of free radicals, the reactive intermediate produced upon photofragmentation of the sulfenate moiety, with the tissue of interest. | 2008-11-06 |
20080275018 | ANTIBACTERIAL AMIDE-MACROCYCLES V - The invention relates to antibacterial amide-macrocycles of formula (I), in which R | 2008-11-06 |
20080275019 | METAL COMPLEX PROTEIN KINASE INHIBITORS - This inventive subject matter relates to novel metal complex protein kinases inhibitors, methods for making such compounds, and methods for using such compounds for treating diseases and disorders mediated by kinase activity. | 2008-11-06 |
20080275020 | PHARMACEUTICAL FORMULATION - The instant invention provides a pharmaceutical composition comprised of a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor, one or more anti-oxidants, microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate and lactose. The composition need not contain ascorbic acid in order to obtain desirable stability. | 2008-11-06 |
20080275021 | PYRROLIDINE DERIVATIVES AS DUAL NK1/NK3 RECEPTOR ANTAGONISTS - The invention relates to pyrrolidine derivatives of formula | 2008-11-06 |
20080275022 | Substituted Quinazolones as Anti-Cancer Agents - The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man. | 2008-11-06 |
20080275023 | N-Hydroxyamides Omege-Substituted with Tricyclic Groups as Histone Deacetylase Inhibitors, Their Preparation and Use in Pharmaceutical Formulations - New N-hydroxyamides of n-alkyl carboxylic acids omega substituted with suitable tricyclic systems characterised by a central 7-membered ring, having activity as inhibitors of histone deacetylase (HDAC). | 2008-11-06 |
20080275024 | CYCLIC MALONAMIDES AS INHIBITORS OF ASS PROTEIN PRODUCTION - This invention relates to novel cyclic malonamides having the formula (I): | 2008-11-06 |
20080275025 | Substituted Lactams and Their Use as Anti-Cancer Agents - This invention relates to certain substituted lactam compounds, particularly caprolactam compounds, which are useful for the treatment of cancer. | 2008-11-06 |
20080275026 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists - Novel compounds according to general formula 1, wherein G | 2008-11-06 |